vancouver british columbia, April 12, 2024 /CNW/ – PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA) has applied to the British Columbia Securities Commission for approval of a Controlled Cease and Desist Trade Order (“MCTO”) pursuant to: We announced that. National Policy 12-203 – Suspension order for continued failure to disclose (“NP 12-203”). If granted, our Chief Executive Officer and Chief Financial Officer will be prohibited from trading in our securities until the required filings (as defined below) and all continuous disclosure requirements have been met. Masu. was filed by us and the MCTO was cancelled. While the MCTO is in effect, the public will continue to be able to trade our publicly traded securities. Although an application for an MCTO has been made, there is no guarantee that the MCTO will be granted.
The Company anticipates that it will be unable to file audited annual consolidated financial statements for the ended fiscal year. December 31, 2023 (the “Financial Statements”) and related management discussion and analysis, as well as the CEO and CFO certifications for the same period (collectively, the Financial Statements and the “Required Documents”), by the financial statement filing deadline. Must be submitted. April 29, 2024 (“Submission Deadline”).
Our inability to make the required filings by the filing deadlines is due to delays in our ability to pay our auditor's (“Auditor's”) outstanding invoices and retainage. The Company is currently negotiating debt or equity financing in an amount sufficient to resolve amounts owed to its auditors. The Company expects to be in a position to cure any default by making the required filings on the same day or earlier. June 29, 2024. If an MCTO is granted, it will remain in effect until the required filings are made.
We will follow the alternative information guidelines set forth in Sections 9 and 10 of NP 12-203 to the extent required filings are outstanding.
About PanGenomic Health
PanGenomic Health is a precision health company that has developed a self-care digital platform that provides personalized, evidence-based information about natural therapies. Our initial focus is mental health support.was registered as british columbia As a benefits company, PanGenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to each individual's health profile.
This news release contains certain statements that may be considered “forward-looking statements,” including statements regarding services provided by PanGenomic Health and consideration paid to PanGenomic Health. “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “predict”, “should”, “believe” The use of words such as '' is intended to identify forward-looking statements. Although PanGenomic Health believes that the expectations and assumptions underlying the forward-looking statements are reasonable, PanGenomic Health can give no assurance that the forward-looking statements will prove to be correct. You should not place undue reliance on forward-looking statements. Forward-looking statements refer to future events or conditions and, by their nature, involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results may not be as expected due to a number of factors and risks, including various risk factors described in his PanGenomic Health disclosure document located on his PanGenomic Health profile at www.sedarplus.ca. The results may differ significantly from those shown.
The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
SOURCE PanGenomic Health Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/12/c7203.html
